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GLIOBLASTOMA EGFR MUTATION PREDICTS THE RESPONSE
TO CYTOTOXIC AND TARGETED THERAPIES
Several molecular aberrations in glioblastoma have been shown to
have prognostic significance, and investigations of targeted ther-
apies for glioma patients are ongoing. Here, Wachsberger and
colleagues demonstrate that overexpression of a constitutively
active form of the epidermal growth factor receptor (EGFR) found
in some glioblastomas sensitizes cells to both multimodal cyto-
toxic therapy and cetuximab (1). The data further indicate that
EGFR mutation may predispose gliomas to defective homolo-
gous recombination repair (HRR). These findings are relevant to
future clinical trials, and suggest that targeted agents may achieve
the greatest benefit in glioma patients who have been stratified
according to molecular markers.
MicroRNA MEDIATES THE CELLULAR RESPONSE TO DNA
DAMAGE
DNA damage triggers a signaling cascade that affects expression,
subcellular localization, and activity of mediators; the strength
and nature of molecular interactions; and chromatin structure.
Ongoing discovery of novel effectors has amplified understanding
of the complex network that mediates the DNA damage response
(DDR). Recent evidence demonstrates that genotoxic stress regu-
lates expression of distinct microRNAs (miRNA), some of which
have been shown to directly influence expression of DDR effectors
including ATM, DNA-PKcs, and BRCA1. The links between miR-
NAs and the DDR are summarized here by Wright and colleagues,
as are the implications of future investigation into this emerging
field (2).
MODULATION OF DOUBLE-STRAND BREAK REPAIR
PATHWAYS TO RADIOSENSITIZE CANCER CELLS
Disparate sensitivity to the cytotoxic effects of radiation mediates
selective tumor cell killing with relative preservation of normal
tissues. Significant effort has been dedicated to understanding
the mechanisms underlying differential radiosensitivity with the
ultimate goal of enhancing the therapeutic ratio of ionizing radi-
ation. Homologous recombinational repair is among the primary
pathways utilized by cells to process otherwise lethal DNA damage,
and is therefore a promising target to improve the efficacy of radi-
ation therapy. The major pathways of double-strand break repair
are summarized here by Mladenov and colleagues, as are potential
targets for radiosensitizing cancer cells (3).
RADIATION-INDUCED SECOND NEOPLASMS
Every year, more than 700 childhood cancer survivors will join
the 300,000 individuals in the United States who have survived
their cancer diagnoses, but will struggle with the consequences of
the treatments that cured them. Twenty-five years after the first
cancer diagnosis, the death rate due to subsequent malignancies
exceeds that due to all other causes. Technological advances have
transformed the delivery of radiation, resulting in more confor-
mal radiation plans. We must investigate whether the benefit of
decreasing acute side effects comes at a cost of lower-dose radia-
tion distributed throughout the child’s body that may increase the
risk of fatal radiation-induced cancers. Braunstein and colleagues
highlight such investigations into the current state of epidemio-
logic modeling and radiotherapy delivery data and their impacts
on patient care (4).
THE COMBINATION OF NOVEL TARGETED MOLECULAR
AGENTS AND RADIATION IN THE TREATMENT OF PEDIATRIC
GLIOMAS
A comprehensive, cutting edge approach to gliomas requires first a
critical understanding of the molecular underpinnings of glioma
pathogenesis and response to therapy. Advances in molecular,
genetic, and biochemical technologies have provided unprece-
dented insight into glioma biology and these are reviewed herein
by Dasgupta and colleagues (5). Targeted therapeutics are avail-
able for many implicated pathways; however, follow up biolog-
ical studies defining the appropriate, most effective agents for
each alteration are lacking. Clinical studies must be designed
that collect and harness molecular data within prospective tri-
als, in order to generate pre-clinical and clinical data that will
determine the best combination of agents for each molecular
subtype.
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IONIZING RADIATION IN GLIOBLASTOMA INITIATING CELLS
Rivera and colleagues explore the mechanisms underlying radi-
ation resistance in GBM initiating cells (GICs) that are critical
to enhanced therapeutic efficacy against neural progenitor cells
(NPCs) (6) The importance of this approach is highlighted by
several recent reports of improved glioma control and clinical
outcome when aggressive therapy and higher doses of radiation
are administered to the adult human subventricular zone, which
constitutes the largest area of neurogenesis and houses the great-
est concentration of NPCs. Such approaches are now possible with
our modern arsenal of sophisticated dose delivery technology, with
which we can modulate the dose to substructures of the brain.
HYPOFRACTIONATED RADIATION AND MOUSE MODELS OF
NON-SMALL CELL LUNG CANCER
Recent clinical trials have demonstrated high rates of long-term
local control and survival from early stage non-small cell lung can-
cer (NSCLC) treated with stereotactic body radiotherapy (SBRT).
Compared to conventionally fractionated radiation regimens,
the success of SBRT for NSCLC suggests that hypofractionated
irradiation may induce distinct molecular pathways to enhance
cell killing. Using two genetically engineered mouse models of
NSCLC, Perez and colleagues demonstrate superior tumor control
with hypofractionated radiation. The cellular response to SBRT
is incompletely understood, but the genetic reagents described
here will be useful to elucidating the molecular mechanisms that
underlie the SBRT DDR (7).
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